XLO Stock Price, Xilio Therapeutics, Inc. Quote, Chart

Market Summary

USD1.09-0.06

Market Closed

-5.22%

XLO Alerts

1 major insider buys recently.

XLO Stock Price

View Fullscreen

XLO RSI Chart

XLO Valuation

Market Cap

37.6M

Price/Earnings (Trailing)

-0.49

Price/Free Cashflow

-0.54

XLO Price/Earnings (Trailing)

XLO Profitability

Return on Equity

-207.53%

Return on Assets

-125.44%

Free Cashflow Yield

-183.91%

XLO Fundamentals

XLO Earnings

Earnings (TTM)

-76.4M

Earnings Growth (Yr)

21.31%

Earnings Growth (Qtr)

-5.56%

Breaking Down XLO Revenue

Last 7 days

-13.5%

Last 30 days

53.5%

Last 90 days

78.7%

Trailing 12 Months

-66.0%

How does XLO drawdown profile look like?

XLO Financial Health

Current Ratio

3.02

XLO Investor Care

Shares Dilution (1Y)

25.63%

Diluted EPS (TTM)

-2.78

Tracking the Latest Insider Buys and Sells of Xilio Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 02, 2024	gilead sciences, inc.	bought	368,790	0.76	485,250	-
Feb 08, 2024	atlas venture fund xi, l.p.	sold	-469	0.64	-733	-
Feb 08, 2024	atlas venture fund xi, l.p.	sold	-170	0.64	-267	-
Jan 12, 2024	atlas venture fund xi, l.p.	sold	-1,278	0.83	-1,540	-
Jan 12, 2024	atlas venture fund xi, l.p.	sold	-464	0.83	-560	-
Jan 11, 2024	atlas venture fund xi, l.p.	sold	-1,362	0.87	-1,566	-
Jan 11, 2024	atlas venture fund xi, l.p.	sold	-495	0.87	-569	-
Dec 10, 2021	bain capital life sciences investors, llc	bought	241,202	9.64809	25,000	-
Dec 09, 2021	bain capital life sciences investors, llc	bought	39,485	9.8442	4,011	-
Dec 08, 2021	bain capital life sciences investors, llc	bought	129,474	9.6206	13,458	-

Which funds bought or sold XLO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	added	1.37	-1,382,250	496,392	-%
Feb 26, 2024	Virtu Financial LLC	new	-	6,000	6,000	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	new	-	16,693	16,693	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	28,280	28,280	-%
Feb 14, 2024	Royal Bank of Canada	added	33.71	-1,000	-	-%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	added	40.73	-147,600	85,515	-%
Feb 14, 2024	Laurion Capital Management LP	reduced	-16.09	-229,573	64,266	-%
Feb 14, 2024	ArrowMark Colorado Holdings LLC	new	-	45,855	45,855	-%
Feb 14, 2024	Rock Springs Capital Management LP	unchanged	-	-2,247,580	792,417	0.02%

Are Funds Buying or Selling XLO?

Are funds buying XLO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own XLO

No. of Funds

XLO Alerts

1 major insider buys recently.

Unveiling Xilio Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	rock springs capital management lp	8.71%	3,003,259	SC 13G/A
Apr 05, 2024	gilead sciences, inc.	19.9%	7,345,473	SC 13G
Feb 14, 2024	rock springs capital management lp	5.23%	1,440,759	SC 13G
Feb 06, 2024	octagon capital advisors lp	0%	0	SC 13G/A
Feb 05, 2024	octagon capital advisors lp	6.48%	1,785,000	SC 13G/A
Apr 10, 2023	mrl ventures fund llc	5.4%	1,483,414	SC 13G
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Jan 25, 2023	octagon capital advisors lp	8.83%	2,425,000	SC 13G
Dec 29, 2022	flynn james e	0%	0	SC 13G/A
Nov 14, 2022	ra capital management, l.p.	0%	0	SC 13G/A

Recent SEC filings of Xilio Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	424B5	Prospectus Filed
Apr 05, 2024	SC 13G/A	Major Ownership Report
Apr 05, 2024	SC 13G	Major Ownership Report
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	3	Insider Trading
Apr 01, 2024	S-8	Employee Benefits Plan
Apr 01, 2024	8-K	Current Report
Apr 01, 2024	10-K	Annual Report
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	8-K	Current Report

Peers (Alternatives to Xilio Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.9B	6.8B	-0.89%	-25.81%	-8.47	5.83	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.46%	-30.31%	-41.72	10.05	76.23%	61.08%
BMRN	16.9B	2.4B	5.17%	-8.18%	100.76	6.98	15.42%	18.43%
INCY	11.7B	3.7B	-8.90%	-30.41%	19.5	3.15	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-13.99%	-44.77%	-10.87	14.48	425.83%	18.94%
BBIO	4.4B	-	-15.28%	57.81%	-6.75	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-11.84%	-2.48%	-14.08	12.45	440.80%	-27.84%
ARWR	3.0B	240.7M	-11.98%	-22.42%	-10	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.29%	-15.38%	-45.71	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-3.94%	-8.31%	24.94	4.47	85.90%	-14.05%
NVAX	572.4M	983.7M	-12.98%	-52.88%	-1.05	0.58	-50.36%	17.16%
CRBP	395.6M	881.7K	7.90%	326.47%	-8.87	466.16	-77.61%	-5.33%
INO	233.7M	4.9M	-13.94%	-3.10%	-1.73	48.02	-54.97%	51.71%
IBIO	6.2M	2.1M	63.30%	36.92%	-0.23	2.14	-13.45%	66.37%

Xilio Therapeutics, Inc. News

Latest updates

Xilio Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet											(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-21.7%	61.00	78.00	92.00	112	139	157	178	196	218	121	36.00
Current Assets	-25.4%	48.00	64.00	78.00	97.00	124	142	163	181	203	106	21.00
Cash Equivalents	-22.6%	46.00	60.00	75.00	93.00	120	139	159	177	200	100	21.00
Net PPE	-6.7%	6.00	6.00	7.00	7.00	7.00	8.00	7.00	7.00	8.00	7.00	7.00
Liabilities	-4.9%	24.00	25.00	25.00	27.00	34.00	31.00	34.00	30.00	33.00	34.00	42.00
Current Liabilities	-5.7%	16.00	17.00	16.00	16.00	21.00	17.00	18.00	12.00	13.00	13.00	22.00
Shareholder's Equity	-29.9%	37.00	52.00	67.00	85.00	106	126	144	166	185	-	-
Retained Earnings	-5.7%	-325	-307	-291	-271	-249	-226	-206	-182	-160	-141	-85.09
Additional Paid-In Capital	0.6%	362	360	358	357	355	353	351	348	346	5.00	2.00
Shares Outstanding	0.3%	28.00	28.00	28.00	27.00	27.00	27.00	27.00	27.00	27.00	-	1.00
Float	-	-	-	68.00	-	-	-	70.00	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-0.4%	-13,427	-13,369	-16,574	-25,250	-18,223	-19,909	-16,756	-20,835	-17,162	-20,719	-20,136	-22,734	-	-
Share Based Compensation	3.7%	1,930	1,861	1,800	1,791	1,815	1,871	2,709	2,029	2,071	1,091	1,002	794	-	-
Cashflow From Investing	-	-	-	-316	-170	-509	-333	-771	-254	-378	-114	-438	-170	-	-
Cashflow From Financing	26.9%	-1,634	-2,236	-992	-1,688	-21.00	-22.00	-21.00	-5.00	115,826	301	-349	144,890	-	-

XLO Income Statement

2023-12-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses
Research and development	$ 52,136	$ 59,201
General and administrative	26,997	29,948
Total operating expenses	79,133	89,149
Loss from operations	(79,133)	(89,149)
Other income, net
Other income, net	2,729	927
Total other income, net	2,729	927
Net loss	(76,404)	(88,222)
Comprehensive loss	$ (76,404)	$ (88,222)
Net loss per share, basic (in dollars per share)	$ (2.78)	$ (3.22)
Net loss per share, diluted (in dollars per share)	$ (2.78)	$ (3.22)
Weighted average common shares outstanding, basic (in shares)	27,496,107	27,392,087
Weighted average common shares outstanding, diluted (in shares)	27,496,107	27,392,087

XLO Balance Sheet

2023-12-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 44,704	$ 120,385
Prepaid expenses and other current assets	3,423	4,111
Total current assets	48,127	124,496
Restricted cash	1,587	1,562
Property and equipment, net	5,942	7,255
Operating lease right-of-use asset	5,125	5,585
Other non-current assets	145	267
Total assets	60,926	139,165
Current liabilities
Accounts payable	1,050	3,125
Accrued expenses	10,497	10,327
Operating lease liability, current portion	1,047	918
Note payable, current portion	3,315	6,667
Other current liabilities	48	82
Total current liabilities	15,957	21,119
Note payable, net of current portion		3,165
Operating lease liability, net of current portion	8,142	9,189
Other non-current liabilities		45
Total liabilities	24,099	33,518
Commitments and contingencies (Note 8)
Stockholders' equity
Preferred stock, $0.0001 par value; 5,000,000 shares authorized, no shares issued or outstanding
Common stock, $0.0001 par value; 200,000,000 shares authorized at December 31, 2023 and December 31, 2022; 27,613,263 shares issued and 27,607,646 shares outstanding at December 31, 2023; 27,471,607 shares issued and 27,425,447 shares outstanding at December 31, 2022	3	3
Additional paid-in capital	362,336	354,752
Accumulated deficit	(325,512)	(249,108)
Total stockholders' equity	36,827	105,647
Total liabilities and stockholders' equity	$ 60,926	$ 139,165

About Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

CEO	Dr. Rene Russo BCPS, Pharm.D, Pharm.D.
WEBSITE	https://xiliotx.com
INDUSTRY	Biotechnology
EMPLOYEES	84

Xilio Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Xilio Therapeutics, Inc.? What does XLO stand for in stocks?

XLO is the stock ticker symbol of Xilio Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Xilio Therapeutics, Inc. (XLO)?

As of Mon Apr 22 2024, market cap of Xilio Therapeutics, Inc. is 37.58 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XLO stock?

You can check XLO's fair value in chart for subscribers.

What is the fair value of XLO stock?

You can check XLO's fair value in chart for subscribers. The fair value of Xilio Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Xilio Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for XLO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Xilio Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether XLO is over valued or under valued. Whether Xilio Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Xilio Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XLO.